Prostatilen Dosage: How Much to Take, When & How

Prostatilen Dosage: How Much to Take, When & How

Disclaimer: This guide is for educational purposes only and does not constitute medical advice. Prostatilen is not approved by the FDA or EMA and is primarily available in Russia and Eastern Europe. Consult a qualified healthcare provider before using this or any peptide compound, especially if you have existing health conditions, take medications, or have allergies to bovine proteins.

Overview

Prostatilen is a bovine prostate-derived peptide bioregulator used clinically to support prostate health, manage benign prostatic hyperplasia (BPH), and improve urogenital function. It comes in two primary administration forms: injectable and suppository. The injectable form is the most studied and widely used, with dosing typically ranging from 5–10 mg daily. Suppository formulations contain 30 mg per unit and are dosed once daily. Treatment cycles typically last 5–10 days, with clinical effects usually appearing after 2–3 injections and reaching maximum benefit after 5–6 injections.

Standard Dosing Protocol

Injectable Form (Most Common)

Standard Dose: 5–10 mg once daily via intramuscular (IM) injection

Typical Cycle: 5–10 consecutive days

Frequency: Once per day, preferably at the same time each morning or evening

Administration Route: Intramuscular injection (IM)

The 5 mg dose is generally considered the entry-level or conservative starting point, while 10 mg represents the upper range for standard therapeutic use. Clinical research shows that effects typically emerge within the first 2–3 injections, with maximum therapeutic benefit occurring around injections 5–6. Most treatment courses do not extend beyond 10 consecutive days.

Suppository Form (Topical)

Standard Dose: 1 suppository (30 mg) once daily

Typical Cycle: 5–10 consecutive days

Administration: Rectal insertion, once daily (typically evening)

The suppository formulation provides an alternative for those unable or unwilling to use injections. The 30 mg suppository is approximately 3–6 times the injectable dose on a milligram basis, reflecting differences in bioavailability between routes.

Dosing by Goal

While Prostatilen is primarily indicated for prostate and urogenital health, clinical evidence suggests different dosing approaches may be optimized for specific outcomes:

For Prostate Health & BPH Symptom Relief

Dose: 5–10 mg IM daily or 30 mg suppository daily

Duration: 5–10 days

Expected Timeline: Symptom improvement (reduced dysuria, improved urination) typically appears within 2–3 days; maximum relief by day 5–6

This is the primary clinical use with the most robust observational evidence. Both injectable and suppository forms show efficacy for reducing inflammatory markers and improving urinary symptoms in chronic prostatitis patients.

For Anti-Inflammatory & Immune Support

Dose: 5 mg IM daily (lower end of range)

Duration: 5–10 days

Expected Timeline: Anti-inflammatory effects (reduced ESR, fibrinogen, normalized T-lymphocyte counts) appear within the 5–10 day treatment window

Lower doses (5 mg) appear sufficient for immunomodulatory effects based on observational studies in pyelonephritis and chronic prostatitis patients. Some evidence suggests clinical effects manifest fully within a 5-day course.

For Sexual Function & Spermatogenesis

Dose: 5–10 mg IM daily

Duration: 10 days (full cycle)

Expected Timeline: Improvements in sperm motility and sexual function emerge by day 7–10

The single RCT examining spermatogenesis used a 10-day course, suggesting that shorter cycles may be suboptimal for reproductive outcomes. The 10-day duration appears necessary for maximum effect on spermatogenesis and copulative function.

For Sleep Quality (Incidental Benefit)

Dose: 5–10 mg IM daily

Duration: 5–10 days

Expected Timeline: Sleep improvements reported in 96.7% of patients, with maximum effect by day 5–6

Sleep improvement appears as a secondary benefit in prostatitis patients rather than a primary indication, suggesting standard prostate-health dosing is appropriate if sleep is a goal.

How to Administer

Injectable Administration (IM)

1. Preparation: Prostatilen is typically supplied as a powder in a vial, requiring reconstitution with supplied diluent or sterile saline immediately before injection
2. Sterility: Use aseptic technique—clean the rubber stopper with an alcohol swab and allow to dry before drawing up the dose
3. Injection Site: Intramuscular injection is standard, typically administered into the gluteal muscle (buttock) or quadriceps
4. Needle Gauge: Usually a 25–27 gauge needle; 1–1.5 inch needle length is typical for IM injection
5. Timing: Inject at the same time daily to maintain consistent levels
6. Storage: Reconstituted solution should be used immediately; unreconstituted vials should be stored according to manufacturer instructions (typically refrigerated)

Suppository Administration

1. Preparation: Remove suppository from packaging
2. Timing: Insert once daily, preferably in the evening before bed
3. Insertion Technique: Lie on your side, gently insert suppository into the rectum approximately 1–1.5 inches, then remain lying down for 10–15 minutes to allow absorption
4. Discomfort: Mild rectal irritation may occur; this typically resolves after the first 1–2 applications
5. Storage: Keep suppositories refrigerated or in a cool place to prevent softening

Cycling & Timing

Standard Treatment Cycle

• Duration: 5–10 consecutive days
• Frequency: Once daily (either AM or PM, consistently)
• Timing: No specific time of day is mandated; morning or evening are equally acceptable if consistent
• Rest Period: After completing a 5–10 day cycle, a rest period is typical before repeating

Repeat Cycling

Clinical evidence does not establish clear protocols for repeat dosing. Most observational studies document single 5–10 day courses. In clinical practice in Russia and Eastern Europe, repeat cycles are sometimes separated by intervals of 1–3 months, though optimal rest duration between cycles remains undefined.

Cycling for Chronic Conditions

For chronic prostatitis or persistent BPH symptoms, some clinicians may recommend:

• Cycle 1: 10 days of daily injections
• Rest: 4–8 weeks
• Cycle 2: Repeat 10-day course if needed

This approach balances therapeutic benefit with the principle of cycling (avoiding continuous long-term use without established long-term safety data).

Beginner vs Advanced Dosing

Beginner Protocol

• Starting Dose: 5 mg IM daily
• Duration: 5 days initially
• Route: Injectable form (better-studied, more flexible dosing)
• Monitoring: Assess tolerance and symptom response
• Escalation: If well-tolerated and symptoms persist, extend to day 10 or increase to 10 mg for second cycle

Rationale: Starting at the lower end (5 mg) allows assessment of individual tolerance and minimizes risk of transient adverse effects like injection site reactions or temporary urinary symptom flares.

Advanced Protocol

• Starting Dose: 10 mg IM daily
• Duration: Full 10-day course
• Route: Injectable form or combination with suppository for additional effect
• Frequency: Potentially combining IM injection (5–10 mg) with evening suppository (30 mg) for enhanced anti-inflammatory effect
• Cycling: More aggressive repeat cycling (every 6–8 weeks) if managing symptomatic chronic prostatitis

Rationale: Experienced users may tolerate higher doses and benefit from longer initial cycles. Combination routes (injectable + suppository) have not been formally studied but may provide complementary benefits.

Common Dosing Mistakes

1. Using Suppository as Primary Therapy Without Injectable Backup

Suppositories are convenient but less bioavailable. If targeting specific outcomes like improved spermatogenesis or significant anti-inflammatory effects, injectable form is better-supported by evidence.

2. Stopping Treatment Too Early

Many users stop after 3–5 days if they don't see dramatic immediate results. Clinical evidence shows maximum benefit emerges around days 5–6 of treatment, so premature discontinuation may miss the therapeutic window.

3. Continuously Dosing Without Cycling

Long-term safety data beyond 10-day courses is absent. Continuous daily dosing without breaks is not supported by clinical evidence and may reduce responsiveness over time.

4. Starting at 10 mg Without Individual Assessment

Beginning at the higher dose increases risk of local injection site reactions or transient worsening of urinary symptoms (an early adverse effect reported in the literature). Starting at 5 mg allows safe dose titration.

5. Inconsistent Injection Timing

Dosing at random times throughout the day may reduce efficacy. Consistent once-daily timing (ideally the same time each day) supports stable tissue levels and optimal response.

6. Exceeding 10 mg Daily Dose

No clinical evidence supports doses exceeding 10 mg daily. Higher doses are not more effective and increase adverse effect risk without additional benefit.

7. Neglecting Reconstitution Requirements

Injectable Prostatilen requires proper reconstitution. Using incorrect diluent, expired diluent, or allowing reconstituted solution to sit more than a few hours reduces potency.

Dosing Summary Table

Practical Dosing Recommendations

For Most Users: Begin with 5 mg IM daily for 5 days. If tolerated well and symptoms improve, extend to day 10. Wait 4–8 weeks, then repeat if needed.

For Chronic/Symptomatic Cases: Use 10 mg IM daily for the full 10-day cycle, repeat every 8 weeks as needed.

For Those Avoiding Injections: 30 mg suppository once daily, 5–10 days, with understanding that evidence is slightly less robust than injectable form.

Cost Consideration: At $30–$90 per month with typical 5–10 day cycles, a single treatment course costs approximately $5–$30, making repeat cycling affordable.

Summary

Prostatilen dosing is straightforward: 5–10 mg IM daily or 30 mg suppository daily for 5–10 consecutive days. Most clinical benefit emerges within days 5–6, and cycles should not exceed 10 days without medical supervision. Beginners should start at the lower end (5 mg) and shorter duration (5 days), escalating only after assessing tolerance. Injectable forms have superior evidence to suppositories. Rest periods of 4–8 weeks between cycles are prudent until long-term safety is better characterized. Consistent daily timing, proper reconstitution (for injectables), and adherence to the full cycle duration optimize therapeutic outcomes while minimizing side effects.